Other research analysts have also recently issued reports about the stock. Chardan Capital raised their price objective on shares of Uniqure from $70.00 to $100.00 and gave the stock a buy rating in a research note on Monday, March 4th. Cantor Fitzgerald reissued a buy rating and set a $81.00 price objective on shares of Uniqure in a research note on Thursday, March 7th. HC Wainwright reissued a buy rating on shares of Uniqure in a research note on Tuesday, February 26th. SunTrust Banks raised their price objective on shares of Uniqure to $76.00 and gave the stock a buy rating in a research note on Tuesday, May 7th. Finally, Zacks Investment Research raised shares of Uniqure from a sell rating to a hold rating in a research note on Thursday, January 17th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and twelve have given a buy rating to the company’s stock. Uniqure presently has a consensus rating of Buy and an average price target of $75.82.
Shares of Uniqure stock opened at $59.74 on Wednesday. The company has a debt-to-equity ratio of 0.38, a current ratio of 9.51 and a quick ratio of 9.51. Uniqure has a 12-month low of $21.98 and a 12-month high of $69.60. The stock has a market capitalization of $2.26 billion, a price-to-earnings ratio of -25.53 and a beta of 0.99.
In other Uniqure news, CEO Matthew C. Kapusta sold 8,000 shares of Uniqure stock in a transaction that occurred on Wednesday, May 15th. The shares were sold at an average price of $58.38, for a total value of $467,040.00. Following the completion of the sale, the chief executive officer now directly owns 421,730 shares of the company’s stock, valued at approximately $24,620,597.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Christian Klemt sold 1,546 shares of Uniqure stock in a transaction that occurred on Tuesday, April 16th. The stock was sold at an average price of $57.18, for a total transaction of $88,400.28. Following the completion of the sale, the insider now directly owns 54,539 shares of the company’s stock, valued at $3,118,540.02. The disclosure for this sale can be found here. Insiders sold a total of 82,922 shares of company stock valued at $5,223,849 over the last ninety days. 1.56% of the stock is owned by corporate insiders.
A number of hedge funds have recently added to or reduced their stakes in the business. Harvest Group Wealth Management LLC purchased a new stake in Uniqure in the 1st quarter worth approximately $26,000. Kore Private Wealth LLC acquired a new position in Uniqure during the 1st quarter valued at about $30,000. Advisor Group Inc. boosted its stake in Uniqure by 5.3% during the 4th quarter. Advisor Group Inc. now owns 9,966 shares of the biotechnology company’s stock valued at $288,000 after purchasing an additional 502 shares during the period. Pearl River Capital LLC acquired a new position in Uniqure during the 1st quarter valued at about $32,000. Finally, SEI Investments Co acquired a new position in Uniqure during the 1st quarter valued at about $35,000. 61.30% of the stock is owned by hedge funds and other institutional investors.
Uniqure Company Profile
uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. It engages in developing AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia B; AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-130, a gene therapy for the treatment of Huntington's disease; and AMT-126, for the treatment of heart failure.
Read More: Price to Earnings Ratio (PE)
Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.